Molecular Cancer Therapeutics: 13 (9)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther September 1 2014 13 (9) 2139-2139;

Review

Review

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

Clémence Feneyrolles, Aurélia Spenlinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé and Aziz Yasri

Mol Cancer Ther September 1 2014 13 (9) 2141-2148; DOI:10.1158/1535-7163.MCT-13-1083

Small Molecule Therapeutics

Small Molecule Therapeutics

Direct Inhibition of Choline Kinase by a Near-Infrared Fluorescent Carbocyanine

Sean P. Arlauckas, Anatoliy V. Popov and Edward J. Delikatny

Mol Cancer Ther September 1 2014 13 (9) 2149-2158; DOI:10.1158/1535-7163.MCT-14-0085
Small Molecule Therapeutics

Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma

Anaïs Balbous, Brigitte Renoux, Ulrich Cortes, Serge Milin, Karline Guilloteau, Thibaut Legigan, Pierre Rivet, Odile Boissonnade, Sébastien Martin, Caroline Tripiana, Michel Wager, René Jean Bensadoun, Sébastien Papot and Lucie Karayan-Tapon

Mol Cancer Ther September 1 2014 13 (9) 2159-2169; DOI:10.1158/1535-7163.MCT-13-1038
Small Molecule Therapeutics

Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)

Jessica J. Huck, Mengkun Zhang, Jerome Mettetal, Arijit Chakravarty, Karthik Venkatakrishnan, Xiaofei Zhou, Rob Kleinfield, Marc L. Hyer, Karuppiah Kannan, Vaishali Shinde, Andy Dorner, Mark G. Manfredi, Wen Chyi Shyu and Jeffrey A. Ecsedy

Mol Cancer Ther September 1 2014 13 (9) 2170-2183; DOI:10.1158/1535-7163.MCT-14-0027
Small Molecule Therapeutics

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

Yi-Xiang Zhang, Ewa Sicinska, Jeffrey T. Czaplinski, Stephen P. Remillard, Samuel Moss, Yuchuan Wang, Christopher Brain, Alice Loo, Eric L. Snyder, George D. Demetri, Sunkyu Kim, Andrew L. Kung and Andrew J. Wagner

Mol Cancer Ther September 1 2014 13 (9) 2184-2193; DOI:10.1158/1535-7163.MCT-14-0387

Large Molecule Therapeutics

Large Molecule Therapeutics

EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein

Dmitrij Hristodorov, Manal Amoury, Radoslav Mladenov, Judith Niesen, Katharina Arens, Nina Berges, Lea Hein, Stefano Di Fiore, Anh-Tuan Pham, Michael Huhn, Wijnand Helfrich, Rainer Fischer, Theo Thepen and Stefan Barth

Mol Cancer Ther September 1 2014 13 (9) 2194-2202; DOI:10.1158/1535-7163.MCT-13-0781

Cancer Biology and Signal Transduction

Cancer Biology and Signal Transduction

Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer

Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma and George R. Stark

Mol Cancer Ther September 1 2014 13 (9) 2203-2214; DOI:10.1158/1535-7163.MCT-14-0013

Companion Diagnostics and Cancer Biomarkers

Companion Diagnostics and Cancer Biomarkers

Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro

Naoki Mine, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff and Takumi Kawabe

Mol Cancer Ther September 1 2014 13 (9) 2215-2225; DOI:10.1158/1535-7163.MCT-13-0808
Companion Diagnostics and Cancer Biomarkers

Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy

Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joan Maurel, Nuria Rodríguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrada, Esther Díaz-López, Antonio Sánchez, Rosario Madero, Paloma Cejas and Jaime Feliu

Mol Cancer Ther September 1 2014 13 (9) 2226-2237; DOI:10.1158/1535-7163.MCT-13-1109
Companion Diagnostics and Cancer Biomarkers

Epidermal Growth Factor–like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer

Torben Frøstrup Hansen, Boye Schnack Nielsen, Flemming Brandt Sørensen, Anders Johnsson and Anders Jakobsen

Mol Cancer Ther September 1 2014 13 (9) 2238-2245; DOI:10.1158/1535-7163.MCT-14-0131

Corrections

Corrections

Correction: Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models

Mol Cancer Ther September 1 2014 13 (9) 2246-2247; DOI:10.1158/1535-7163.MCT-14-0497
Corrections

Correction: Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death

Mol Cancer Ther September 1 2014 13 (9) 2248-2249; DOI:10.1158/1535-7163.MCT-14-0537
Corrections

Correction: The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells

Mol Cancer Ther September 1 2014 13 (9) 2250-2250; DOI:10.1158/1535-7163.MCT-14-0586

Main menu

User menu

Search

Table of Contents

Highlights

Review

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Biology and Signal Transduction

Companion Diagnostics and Cancer Biomarkers

Corrections

Issue Highlights

Jump to

Articles

Info for

About MCT